Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme–substrate interactions

The overall predictive ability of molecular modelling, as applied to the cytochrome P450 (CYP) system, is analysed in the light of current developments in a variety of techniques, including X-ray crystallography, molecular biology, enzyme kinetics, molecular mechanics and dynamics, in relation to its relevance to drug metabolism in humans. This review demonstrates that it is possible to generate realistic models for the major human CYPs, which metabolise xenobiotics that compare favourably with crystal structures, and thus may be used to derive substrate binding energies that agree closely with experimental Km values obtained from enzyme kinetics.

[1]  Yuko Ito,et al.  Structural modelling of the human drug-metabolizing cytochromes P450. , 2006, Current medicinal chemistry.

[2]  D. Lewis,et al.  Investigating human P450s involved in drug metabolism via homology with high-resolution P450 crystal structures of the CYP2C subfamily. , 2006, Current drug metabolism.

[3]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[4]  D. Lewis.  P450 structures and oxidative metabolism of xenobiotics. , 2003, Pharmacogenomics.

[5]  Eric F. Johnson,et al.  The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.

[6]  Lars Carlsson,et al.  State-of-the-art Tools for Computational Site of Metabolism Predictions: Comparative Analysis, Mechanistical Insights, and Future Applications , 2007, Drug metabolism reviews.

[7]  Jordi Mestres,et al.  Structure conservation in cytochromes P450 , 2004, Proteins.

[8]  Yuko Ito,et al.  Analysis of CYP2D6 substrate interactions by computational methods. , 2008, Journal of molecular graphics & modelling.

[9]  Maurice Dickins,et al.  Compound lipophilicity for substrate binding to human P450s in drug metabolism. , 2004, Drug discovery today.

[10]  R. Obach,et al.  Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[11]  Johann Gasteiger,et al.  Ligand-Based Models for the Isoform Specificity of Cytochrome P450 3A4, 2D6, and 2C9 Substrates , 2007, J. Chem. Inf. Model..

[12]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[13]  Slobodan Petar Rendic.  Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[14]  D. Lewis,et al.  Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. , 2003, Current medicinal chemistry.

[15]  A. D. Rodrigues,et al.  Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. , 1999, Biochemical pharmacology.

[16]  C David Stout,et al.  Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding. , 2003, Biochemistry.

[17]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[18]  D. Lewis,et al.  Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s. , 2002, Toxicology.

[19]  Eric F. Johnson,et al.  Structure of Mammalian Cytochrome P450 2B4 Complexed with 4-(4-Chlorophenyl)imidazole at 1.9-Å Resolution , 2004, Journal of Biological Chemistry.

[20]  S. Shaik,et al.  Computational Approaches to Cytochrome P450 Function , 2005 .

[21]  D. Lewis.  Modelling human cytochromes P450 involved in drug metabolism from the CYP2C5 crystallographic template. , 2002, Journal of inorganic biochemistry.

[22]  D. Lewis,et al.  Enzyme-Substrate Binding Interaction Energies and Their Application to the Cytochrome P450 System , 2008 .

[23]  Gordon C K Roberts,et al.  Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. , 2004, Journal of medicinal chemistry.

[24]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[25]  D. Lewis,et al.  Cytochromes P450, Oxygen, and Evolution , 2001, TheScientificWorldJournal.

[26]  Yuko Ito,et al.  Cytochrome P450 structures and their substrate interactions , 2005 .

[27]  Frank E. Blaney,et al.  Crystal Structure of Human Cytochrome P450 2D6* , 2005, Journal of Biological Chemistry.

[28]  D. Lewis,et al.  Molecular Modeling and Quantitative Structure–Activity Relationship of Substrates and Inhibitors of Drug Metabolism Enzymes , 2007 .

[29]  D. Lewis,et al.  Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  Sason Shaik,et al.  Quantum mechanical/molecular mechanical investigation of the mechanism of C-H hydroxylation of camphor by cytochrome P450cam: theory supports a two-state rebound mechanism. , 2004, Journal of the American Chemical Society.

[31]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[32]  Stewart B Kirton,et al.  In silico methods for predicting ligand binding determinants of cytochromes P450. , 2004, Current topics in medicinal chemistry.

[33]  C David Stout,et al.  Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen , 2005, Nature Structural &Molecular Biology.

[34]  C David Stout,et al.  Structure of Human Microsomal Cytochrome P450 2C8 , 2004, Journal of Biological Chemistry.

[35]  D. Lewis.  Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. , 2003, Archives of biochemistry and biophysics.

[36]  D. Lewis.  Hydrogen Bonding in Human P450-Substrate Interactions: A Major Contribution to Binding Affinity , 2004, TheScientificWorldJournal.

[37]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[38]  Maurice Dickins,et al.  Substrate SARs in human P450s. , 2002, Drug discovery today.

[39]  D. Lewis,et al.  57 varieties: the human cytochromes P450. , 2004, Pharmacogenomics.

[40]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[41]  D. Lewis.  Guide to Cytochromes P450 : structure and function , 2001 .

[42]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[43]  Hayley S. Brown,et al.  Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies , 2007, Drug metabolism reviews.

[44]  D. Lewis.  Structural Models for Cytochrome P450—Mediated Catalysis , 2003, TheScientificWorldJournal.